Skip to content

Preventing Depressive Relapse in Pregnant Women With Recurrent Depression

Preventing Depressive Relapse in Pregnant Women With Recurrent Depression

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03623620
Enrollment
500
Registered
2018-08-09
Start date
2019-03-12
Completion date
2022-03-21
Last updated
2023-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antenatal Depression, Depression, Pregnancy Related

Keywords

Depression, Pregnancy, Antidepressants, Mindfulness, Medication use during pregnancy, Depression Relapse, Suicidal ideation

Brief summary

The purpose of this investigation is to conduct a pragmatic effectiveness trial comparing digital mindfulness-based cognitive therapy (MBCT) plus usual care to usual care (UC) only among euthymic pregnant women with recurrent depression treated with antidepressants. In the supplemental arms we will investigate the prevalence, severity, longitudinal course, correlates, and predictors of suicidal ideation and behavior among women during pregnancy and the postpartum period.

Detailed description

This study will address a significant gap in the evidence regarding effective approaches to prevent depressive relapse among women with recurrent depression who maintain euthymia using antidepressants and who wish to conceive or who are pregnant. Relapse rates of depression following antidepressant discontinuation among such women has been established, and the efficacy of MBCT in mitigating relapse risk in pregnant women with recurrent depression compared to UC also has been demonstrated. But the effectiveness of MBCT has not been tested in a definitive trial; the question of whether MBCT can mitigate risk for depressive relapse among pregnant women on antidepressants, including among those who discontinue antidepressants proximate to or during pregnancy, also has not been addressed. Reproductive age women with recurrent depression and their healthcare providers need to know, first, if a scalable digital non-pharmacologic prevention approach is superior to UC in community settings, and second, whether MBCT can attenuate risk for depressive relapse among those who elect to discontinue maintenance antidepressant treatment proximate to or during pregnancy. Lastly, the capacity to identify which women are most likely to benefit from a non-pharmacologic or pharmacologic approach personalizes the risk benefit decision making process for reproductive age women on antidepressants planning to conceive or who are pregnant. Investigators will test the relative risk for depressive relapse and reduction of symptom burden between women randomized to digital MBCT or UC, explore the specific benefit of MBCT relative to antidepressant discontinuation, and determine whether a treatment selection algorithm can predict whether MBCT or UC will work best for a specific participant. The supplemental arms of this study will further investigate suicidal ideation and behavior in a perinatal population to better understand the prevalence, severity, longitudinal course, correlates and predictors of suicidal ideation and behavior among women during pregnancy and in the postpartum period. Investigators will use a mixed methods approach of both cross-sectional and longitudinal study designs to characterize a real-world population of pregnant and postpartum women who have endorsed suicidality. Investigators will also use qualitative interviews, self-report instruments, and medical records to explore the extent to which community healthcare professionals providing care to perinatal women report the knowledge base and requisite skills to address suicidal ideation and behavior in this population. MMB for Moms delivers digitally both the content and structure of in-person MBCT, and may be a promising intervention for pregnant women with suicidal ideation. Investigators will also explore the safety, feasibility, and acceptability of enrolling pregnant women with any reports of suicidal ideation or behavior in a proof of concept randomized controlled trial comparing MMB for Moms to enhanced usual care.

Interventions

BEHAVIORALDigital Delivery of Mindfulness-Based Cognitive Therapy

12-week program that emphasizes mindfulness and cognitive behavioral skills

Sponsors

University of Colorado, Boulder
CollaboratorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Pregnant women * Ages 18 or older * History of recurrent major depression prior to pregnancy (at least 2 prior episodes, one of which may be currently treated) * Euthymic or with residual symptoms (PHQ-9 ≤ 9) * No depressive relapse since last menstrual period * Currently or recently received antidepressants (within the three months prior to last menstrual period) * Presence of ongoing community provider

Exclusion criteria

* Diagnosis of bipolar or psychotic disorder * Active mania, psychosis, or substance abuse (within the last 6 months) * Immediate risk of self-harm * Non-English speaking Inclusion and

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Experiencing Relapse of DepressionRandomization through 6 months postpartumDepression relapse from randomization through 6 month postpartum

Countries

United States

Participant flow

Recruitment details

The UPWARD randomized clinical trial was conducted nationally, recruiting euthymic pregnant women with recurrent depression treated with antidepressants. Participant recruitment for UPWARD began March 7, 2019, and concluded July 8, 2020.

Pre-assignment details

745 individuals were eligible after the initial phone screen, 512 completed the baseline interview and surveys (66 were found ineligible during the baseline interview, 20 did not complete baseline surveys within 1 week, and 147 were non-responsive to follow-up), and 500 were randomized (12 were lost to follow up before randomization).

Participants by arm

ArmCount
Digital Delivery of MBCT (Mindful Mood Balance for Moms)
Subjects will receive digital delivery of mindfulness-based cognitive therapy (Mindful Mood Balance for Moms) for 12 weeks, along with the usual care they would receive from their provider. Digital Delivery of Mindfulness-Based Cognitive Therapy: 12-week program that emphasizes mindfulness and cognitive behavioral skills
249
Usual Care
Subjects will receive only usual care, the care they would normally receive from their community provider, for 12 weeks.
251
Total500

Baseline characteristics

CharacteristicDigital Delivery of MBCT (Mindful Mood Balance for Moms)Usual CareTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
249 Participants251 Participants500 Participants
Age, Continuous32.1 years
STANDARD_DEVIATION 4.65
32.2 years
STANDARD_DEVIATION 4.43
32.2 years
STANDARD_DEVIATION 4.54
Ethnicity (NIH/OMB)
Hispanic or Latino
17 Participants29 Participants46 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
232 Participants222 Participants454 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
2 Participants1 Participants3 Participants
Race (NIH/OMB)
Asian
8 Participants9 Participants17 Participants
Race (NIH/OMB)
Black or African American
11 Participants14 Participants25 Participants
Race (NIH/OMB)
More than one race
5 Participants9 Participants14 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
3 Participants2 Participants5 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants6 Participants10 Participants
Race (NIH/OMB)
White
216 Participants210 Participants426 Participants
Sex: Female, Male
Female
249 Participants251 Participants500 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 2490 / 251
other
Total, other adverse events
177 / 249209 / 251
serious
Total, serious adverse events
0 / 2490 / 251

Outcome results

Primary

Number of Participants Experiencing Relapse of Depression

Depression relapse from randomization through 6 month postpartum

Time frame: Randomization through 6 months postpartum

ArmMeasureValue (NUMBER)
Digital Delivery of MBCT (Mindful Mood Balance for Moms)Number of Participants Experiencing Relapse of Depression81 Participants
Usual CareNumber of Participants Experiencing Relapse of Depression111 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026